U.S. flag

An official website of the United States government

NM_000152.5(GAA):c.1537G>A (p.Asp513Asn) AND Glycogen storage disease, type II

Germline classification:
Likely pathogenic (4 submissions)
Last evaluated:
Jul 18, 2023
Review status:
3 stars out of maximum of 4 stars
reviewed by expert panel
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001233657.10

Allele description [Variation Report for NM_000152.5(GAA):c.1537G>A (p.Asp513Asn)]

NM_000152.5(GAA):c.1537G>A (p.Asp513Asn)

Gene:
GAA:alpha glucosidase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
17q25.3
Genomic location:
Preferred name:
NM_000152.5(GAA):c.1537G>A (p.Asp513Asn)
Other names:
NM_000152.5(GAA):c.1537G>A
HGVS:
  • NC_000017.11:g.80110826G>A
  • NG_009822.1:g.14271G>A
  • NM_000152.5:c.1537G>AMANE SELECT
  • NM_001079803.3:c.1537G>A
  • NM_001079804.3:c.1537G>A
  • NP_000143.2:p.Asp513Asn
  • NP_001073271.1:p.Asp513Asn
  • NP_001073272.1:p.Asp513Asn
  • LRG_673t1:c.1537G>A
  • LRG_673:g.14271G>A
  • NC_000017.10:g.78084625G>A
  • NM_000152.3:c.1537G>A
  • NM_000152.4:c.1537G>A
  • p.Asp513Asn
Protein change:
D513N
Links:
dbSNP: rs748047271
NCBI 1000 Genomes Browser:
rs748047271
Molecular consequence:
  • NM_000152.5:c.1537G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001079803.3:c.1537G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001079804.3:c.1537G>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Glycogen storage disease, type II (GSD2)
Synonyms:
ACID ALPHA-GLUCOSIDASE DEFICIENCY; GLYCOGENOSIS, GENERALIZED, CARDIAC FORM; GSD II; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0009290; MedGen: C0017921; Orphanet: 365; OMIM: 232300

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001406261Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Pathogenic
(Dec 9, 2023)
germlineclinical testing

PubMed (2)
[See all records that cite these PMIDs]

SCV001810610Genome-Nilou Lab
criteria provided, single submitter

(ACMG Guidelines, 2015)
Uncertain significance
(Jul 22, 2021)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV004042615ClinGen Lysosomal Storage Disorder Variant Curation Expert Panel
reviewed by expert panel

(clingen_lsd_acmg_specifications_v2-1)
Likely pathogenic
(Jul 18, 2023)
germlinecuration

Citation Link,

SCV005058735Baylor Genetics
criteria provided, single submitter

(ACMG Guidelines, 2015)
Likely pathogenic
(Mar 3, 2024)
unknownclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlinenonot providednot providednot providednot providednot providedclinical testing
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing, curation
not providedunknownunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Lysosomal storage disorders: Novel and frequent pathogenic variants in a large cohort of Indian patients of Pompe, Fabry, Gaucher and Hurler disease.

Thomas DC, Sharma S, Puri RD, Verma IC, Verma J.

Clin Biochem. 2021 Mar;89:14-37. doi: 10.1016/j.clinbiochem.2020.12.002. Epub 2020 Dec 8.

PubMed [citation]
PMID:
33301762

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818
See all PubMed Citations (3)

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV001406261.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (2)

Description

This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 513 of the GAA protein (p.Asp513Asn). This variant is present in population databases (rs748047271, gnomAD 0.006%). This missense change has been observed in individual(s) with Pompe disease (PMID: 33301762). ClinVar contains an entry for this variant (Variation ID: 960182). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GAA protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Genome-Nilou Lab, SCV001810610.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlinenonot providednot providednot providednot providednot providednot providednot provided

From ClinGen Lysosomal Storage Disorder Variant Curation Expert Panel, SCV004042615.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedcurationnot provided

Description

The NM_000152.5: c.1537G>A variant in GAA is a missense variant predicted to cause substitution of aspartic acid by asparagine at amino acid 513 (p.Asp513Asn). This variant has been detected in at least five individuals with Pompe disease. One patient of late-onset Pompe disease had documented GAA deficiency as 8.7% of the normal control level of GAA activity (PMID 33301762). Three siblings from one family had documented reduced GAA enzyme activity within the deficient range (clinical laboratory data). Patient(s) with this variant had documented in a Pompe Registry with the onset of symptoms less than 12 years of age (PMID 31342611). (PP4_Moderate). Of those individuals, one individual was homozygous for the variant, and three siblings were compound heterozygous for the variant and the pathogenic c.-32-13T>G variant (PM3 2.0 points, PMID 33301762, clinical laboratory data) (PM3_Strong). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00006533 (2/30616 alleles) in the South Asian population, which is lower than the ClinGen LSD VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). The computational predictor REVEL gives a score of 0.861 which is above the threshold of 0.7, evidence that correlates with impact on GAA function (PP3). Another missense variant c.1538A>G (p.Asp513Gly) (PMID 31510962, 33560568; ClinVar Variation ID: 638014) in the same codon has been classified as likely pathogenic for Pompe disease by the ClinGen LSD VCEP (PM5_Supporting). There is a ClinVar entry for this variant (Variation ID: 960182). In summary, this variant meets the criteria to be classified as likely pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP (specifications version 2.0): PP4_Moderate, PM3_Strong, PM2_Supporting, PP3, PM5_Supporting. (Classification approved by the ClinGen Lysosomal Diseases VCEP on July 18, 2023).

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Baylor Genetics, SCV005058735.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1unknownunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024